Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis)

Medicine & Life Sciences

• 2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide 100%
• Aggressive Fibromatosis 66%
• Amyloid Precursor Protein Secretases 59%
• 4-(3-((3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)phenyl)thio)phenyl)tetrahydro-2H-pyran-4-carboxamide 16%
• Neoplasms 15%
• Patient Reported Outcome Measures 15%
• APC Genes 9%
• Connective Tissue Cells 9%
• Response Evaluation Criteria in Solid Tumors 8%
• Germ-Line Mutation 7%
• Radiation 5%
• Fibroblasts 5%
• Therapeutics 4%
• Equipment and Supplies 4%
• Morbidity 4%
• Recurrence 3%
• Mutation 3%
• Genes 2%